CVS Will No Longer Reimburse Health Insurers for This Insulin Drug — Fortune

U.S. pharmacy benefit manager CVS will drop Sanofi’s main insulin drug Lantus from the list of medicines it reimburses on behalf of health insurers, dealing a blow to the French drugmaker’s key diabetes business. CVS said it would switch instead to Ely Lilly’s cheaper biosimilar drug Basaglar from 2017. Biosimilars are cheaper copies of protein-based…

via CVS Will No Longer Reimburse Health Insurers for This Insulin Drug — Fortune

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s